Estetrol and the possibilities of its clinical use

被引:6
作者
Krepelka, P. [1 ,2 ,3 ]
机构
[1] Ustav Pro Peci Matku & Dite, Podolske Nabrezi 157, Prague 14700 7, Czech Republic
[2] Katedra Gynekol & Porodnictvi IPVZ, Prague, Czech Republic
[3] 3 LF UK, Katedra Gynekol Porodnictvi, Prague, Czech Republic
来源
CESKA GYNEKOLOGIE-CZECH GYNAECOLOGY | 2021年 / 86卷 / 03期
关键词
estetrol; hormonal contraception; estrogens; drospirenone; complications of hormonal contraception; FETAL ESTROGEN ESTETROL; ORAL ESTETROL; DROSPIRENONE; METABOLISM; ESTRIOL; 15ALPHA-HYDROXYESTRIOL; ENDOCRINE; EXCRETION; BINDING; PROFILE;
D O I
10.48095/cccg2021217
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Combined hormonal contraceptive methods are one of the most commonly used methods of planned parenthood. They show high contraceptive effectiveness, reasonable cycle control and bring several non-contraceptive benefits. A limitation of the widespread use of combined hormonal contraception is the risk of cardiovascular complications in individuals with specific risk factors. The risk of cardiovascular complications is related to the used estrogen component. Currently, the most common use of estrogen in combined hormonal contraception is ethinyl estradiol and estradiol valerate. The good estrogenic part of combined oral contraceptives is estetrol, a hormone produced exclusively by the fetal liver. Estetrol exhibits a tissue-selective receptor activity. Unlike previously used estrogens, it does not negatively affect the production of liver proteins and blood clotting parameters. Estetrol is not a perspective for combined hormonal contraception only. It is also promising for treating and preventing osteoporosis, hormonal therapy of menopausal syndrome, and vulvovaginal atrophy syndrome.
引用
收藏
页码:217 / 221
页数:5
相关论文
共 50 条
[21]   THE URINARY PODOCYTE AND ITS CLINICAL SIGNIFICANCE [J].
Masanori, Hara .
NEPHROLOGY, 2014, 19 :13-13
[22]   New metal-based nanoparticles for intravenous use: requirements for clinical success with focus on medical imaging [J].
Skotland, Tore ;
Iversen, Tore-Geir ;
Sandvig, Kirsten .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2010, 6 (06) :730-737
[23]   Blazing a trail for the clinical use of rapamycin as a geroprotecTOR [J].
Konopka, Adam R. ;
Lamming, Dudley W. .
GEROSCIENCE, 2023, 45 (05) :2769-2783
[24]   The clinical use of Fondaparinux: A synthetic heparin pentasaccharide [J].
Zhang, Yiran ;
Zhang, Meng ;
Tan, Lijuan ;
Pan, Nana ;
Zhang, Lijuan .
GLYCANS AND GLYCOSAMINOGLYCANS AS CLINICAL BIOMARKERS AND THERAPEUTICS, PT B, 2019, 163 :41-53
[25]   Blazing a trail for the clinical use of rapamycin as a geroprotecTOR [J].
Adam R. Konopka ;
Dudley W. Lamming .
GeroScience, 2023, 45 (5) :2769-2783
[26]   Riboflavin - properties, occurrence and its use in medicine [J].
Szczuko, Malgorzata ;
Zietek, Maciej ;
Kulpa, Danuta ;
Seidler, Teresa .
PTERIDINES, 2019, 30 (01) :33-47
[27]   Dienogest A Review of its Use in the Treatment of Endometriosis [J].
McCormack, Paul L. .
DRUGS, 2010, 70 (16) :2073-2088
[28]   Sulfur: Its clinical and toxicologic aspect's [J].
Komarnisky, LA ;
Christopherson, RJ ;
Basu, TK .
NUTRITION, 2003, 19 (01) :54-61
[29]   Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines [J].
Bird, Steven T. ;
Hartzema, Abraham G. ;
Etminan, Mahyar ;
Brophy, James M. ;
Delaney, Joseph. A. C. .
GYNECOLOGICAL ENDOCRINOLOGY, 2013, 29 (04) :365-369
[30]   Clinical Lipidology Roundtable Discussion Clinical use of genetic typing in human lipid disorders [J].
Brown, W. Virgil ;
Breslow, Jan ;
Ballantyne, Christie .
JOURNAL OF CLINICAL LIPIDOLOGY, 2012, 6 (03) :199-207